{
  "dataset": {
    "version": "2026-11-15",
    "sha256": "966d20e4ebd28b02a5bf5709b5733de3f33bebb38b66ba9885ad48a836deddd2",
    "counts": {
      "acts": 47,
      "concepts": 25,
      "edges": 28,
      "obligations": 29,
      "measures": 43,
      "gaps": 32,
      "mitigations": 13,
      "equivalences": 27
    },
    "ledger_seq": 421
  },
  "counts": {
    "eu_to_national": 0,
    "national_to_eu": 5
  },
  "gaps": [
    {
      "id": "gap.nl.gatekeeping",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.referral",
      "obligation_id": "eu.cbhc.prescriptions",
      "measure_id": "nl.ref.gatekeeping",
      "gap_type": "national_only",
      "severity": 2,
      "summary": "GP referral is a condition of reimbursement; Art. 7(7) allows this, but referral notes are not covered by EU mutual recognition (Art. 11 covers prescriptions only), so a referral issued abroad may not be accepted.",
      "verification": "needs_research",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Symptomatic presentation and referral",
      "obligation": {
        "id": "eu.cbhc.prescriptions",
        "article": "Art. 11 with Implementing Directive 2012/52/EU",
        "summary": "Prescriptions for medicinal products and medical devices issued in another Member State are recognised. Referral notes for diagnostics are not covered by this mechanism.",
        "act": {
          "act_id": "celex:32011L0024",
          "title": "Directive 2011/24/EU on the application of patients' rights in cross-border healthcare",
          "short_title": "Directive 2011/24/EU (cross-border care)",
          "url": "https://eur-lex.europa.eu/eli/dir/2011/24/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "nl.ref.gatekeeping",
        "article": "Besluit zorgverzekering (referral for specialist care)",
        "summary": "Specialist medical care is reimbursed on referral by a GP (gatekeeper model).",
        "url": "https://wetten.overheid.nl/BWBR0018492/",
        "verification": "needs_research",
        "act": {
          "act_id": "nl:zvw",
          "title": "Zorgverzekeringswet (Zvw) — Health Insurance Act",
          "short_title": "Zorgverzekeringswet (Zvw) — Health Insurance Act",
          "url": "https://wetten.overheid.nl/BWBR0018450/",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.nl.referral",
          "gap_id": "gap.nl.gatekeeping",
          "kind": "policy",
          "audience": "insurer",
          "summary": "Insurers can state in policy conditions that a referral from a physician in another Member State is accepted.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.nl.wbo.permit",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening",
      "obligation_id": "eu.bss.justification",
      "measure_id": "nl.scr.wbo",
      "gap_type": "exceeds",
      "severity": 2,
      "summary": "The WBO permit regime goes beyond the BSS justification rule: any cancer screening offer, including commercial or AI-supported screening, needs a permit. This is a market-access barrier specific to the Netherlands.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Organised population screening",
      "obligation": {
        "id": "eu.bss.justification",
        "article": "Art. 55",
        "summary": "Every medical exposure must be justified, generically and individually. A radiological procedure on an asymptomatic person for early detection must be part of a health screening programme or have a specific documented justification.",
        "act": {
          "act_id": "celex:32013L0059",
          "title": "Council Directive 2013/59/Euratom laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation (BSS)",
          "short_title": "Directive 2013/59/Euratom (BSS)",
          "url": "https://eur-lex.europa.eu/eli/dir/2013/59/oj",
          "binding": "binding_transposition"
        }
      },
      "measure": {
        "id": "nl.scr.wbo",
        "article": "WBO, permit requirement",
        "summary": "Population screening for cancer, or using ionising radiation, needs a ministerial permit after advice of the Health Council (Gezondheidsraad). This also covers commercial screening offers.",
        "url": "https://wetten.overheid.nl/BWBR0005699/",
        "verification": "secondary",
        "act": {
          "act_id": "nl:wbo",
          "title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "short_title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "url": "https://wetten.overheid.nl/BWBR0005699/",
          "binding": "national"
        }
      },
      "mitigations": [
        {
          "id": "mit.nl.wbo",
          "gap_id": "gap.nl.wbo.permit",
          "kind": "medtech",
          "audience": "medtech",
          "summary": "Plan WBO permit timelines (Health Council advice) in NL market entry for any screening use; position AI tools inside the national programme rather than as stand-alone screening.",
          "reference_measure_id": null
        }
      ]
    },
    {
      "id": "gap.nl.soncos",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.staging_mdt",
      "obligation_id": "eu.ecibc.mdt",
      "measure_id": "nl.mdt.soncos",
      "gap_type": "national_only",
      "severity": 1,
      "summary": "SONCOS volume norms steer purchasing but are national only; no mapping to ECIBC accreditation.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Staging and multidisciplinary tumour board",
      "obligation": {
        "id": "eu.ecibc.mdt",
        "article": "Quality assurance scheme requirements",
        "summary": "Breast cancer services discuss every case in a multidisciplinary team, meet diagnostic timeliness targets and report quality indicators.",
        "act": {
          "act_id": "eu:ecibc-qa-scheme",
          "title": "European Commission Initiative on Breast Cancer (ECIBC): European guidelines and quality assurance scheme for breast cancer services",
          "short_title": "ECIBC guidelines and QA scheme",
          "url": "https://cancer-screening-and-care.jrc.ec.europa.eu/en/ecibc",
          "binding": "soft_law"
        }
      },
      "measure": {
        "id": "nl.mdt.soncos",
        "article": "SONCOS standards",
        "summary": "Professional multidisciplinary standards incl. tumour boards and minimum volumes, used by insurers in purchasing.",
        "url": "https://www.soncos.org/kwaliteit/normeringsrapport/",
        "verification": "cited_unverified",
        "act": {
          "act_id": "nl:soncos",
          "title": "SONCOS Normeringsrapport — multidisciplinary quality standards for oncological care",
          "short_title": "SONCOS Normeringsrapport — multidisciplinary quality standards for oncological care",
          "url": "https://www.soncos.org/kwaliteit/normeringsrapport/",
          "binding": "voluntary"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.wbmv",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.biomarker.germline",
      "obligation_id": "eu.ivdr.devices",
      "measure_id": "nl.gen.wbmv",
      "gap_type": "national_only",
      "severity": 1,
      "summary": "Germline testing concentrated in licensed clinical genetics centres; a CE-marked test alone does not give market access to clinical use.",
      "verification": "secondary",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Germline genetic testing for hereditary cancer",
      "obligation": {
        "id": "eu.ivdr.devices",
        "article": "Art. 5, Art. 48, Annex VIII",
        "summary": "IVDs (FIT, HPV tests, PSA assays, IHC and molecular tests) must be CE-marked; cancer tests and companion diagnostics are generally class C and need a notified body, with EMA or national medicines authority consultation for companion diagnostics.",
        "act": {
          "act_id": "celex:32017R0746",
          "title": "Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)",
          "short_title": "Reg. 2017/746 (IVDR)",
          "url": "https://eur-lex.europa.eu/eli/reg/2017/746/oj",
          "binding": "directly_applicable"
        }
      },
      "measure": {
        "id": "nl.gen.wbmv",
        "article": "WBMV licensing of clinical genetic testing",
        "summary": "Clinical genetic testing (incl. hereditary cancer DNA diagnostics) is a licensed special medical procedure concentrated in the clinical genetics centres.",
        "url": "https://www.rijksoverheid.nl/themas/familie-zorg-en-gezondheid/kwaliteit-van-de-zorg/vergunning-bijzondere-medische-verrichtingen-ziekenhuizen",
        "verification": "secondary",
        "act": {
          "act_id": "nl:wbmv",
          "title": "Wet op bijzondere medische verrichtingen (WBMV) — licensing of special medical procedures incl. clinical genetic testing",
          "short_title": "Wet op bijzondere medische verrichtingen (WBMV) — licensing of special medical procedures incl. clinical genetic testing",
          "url": "https://www.rijksoverheid.nl/themas/familie-zorg-en-gezondheid/kwaliteit-van-de-zorg/vergunning-bijzondere-medische-verrichtingen-ziekenhuizen",
          "binding": "national"
        }
      },
      "mitigations": []
    },
    {
      "id": "gap.nl.breast.age",
      "direction": "national_to_eu",
      "jurisdiction_code": "NL",
      "concept_id": "oncology.dx.screening.breast",
      "obligation_id": "eu.scr.breast",
      "measure_id": "nl.scr.breast",
      "gap_type": "exceeds",
      "severity": 0,
      "summary": "Upper age 75, as in Germany; age-band harmonisation needed when comparing interval cancers.",
      "verification": "cited_unverified",
      "status": "proposed",
      "reviewed_ledger_seq": null,
      "step": "Breast cancer screening (mammography)",
      "obligation": {
        "id": "eu.scr.breast",
        "article": "Point 1 and Annex (breast)",
        "summary": "Offer mammography screening to women aged 50–69; consider 45–49 and 70–74. MRI may be considered where medically appropriate (dense breasts).",
        "act": {
          "act_id": "celex:32022H1214(01)",
          "title": "Council Recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening (2022/C 473/01)",
          "short_title": "Council Rec. 2022 on cancer screening",
          "url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022H1214(01)",
          "binding": "non_binding"
        }
      },
      "measure": {
        "id": "nl.scr.breast",
        "article": "National breast cancer screening programme (RIVM-CvB)",
        "summary": "Biennial mammography for women 50–75.",
        "url": "https://www.rivm.nl/bevolkingsonderzoek-borstkanker",
        "verification": "cited_unverified",
        "act": {
          "act_id": "nl:wbo",
          "title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "short_title": "Wet op het bevolkingsonderzoek (WBO) — Population Screening Act",
          "url": "https://wetten.overheid.nl/BWBR0005699/",
          "binding": "national"
        }
      },
      "mitigations": []
    }
  ],
  "disclaimer": "MVP research dataset compiled by hand from public legal sources; not legal or medical advice. Each row carries a verification level (verified, secondary, cited_unverified, needs_research); only \"verified\" rows were checked against the official text on the dataset date. Gap findings are \"proposed\" until reviewed."
}